News, musings and commentary on pharmaceutical law issues, technology, and litigation.
No advice, though.
Lawyers for consumers and injured people.(No advice on this blog, though) TOLL FREE 855-525-3955
Tuesday, June 12, 2007
Congressional Panel to Consider FDA Drug Safety Bill
Happens today. According to reports, a U.S. House of Representatives subcommittee will take up legislation that gives teeth to the FDA's ability to monitor prescription drug side effects post drug approval.
A draft of the bill includes parts that are tougher than those passed in a similar Senate bill. One section limits consumer drug advertisements and symbols on newly approved medications to alert patients.